The Her-2/neu gene and protein in breast cancer 2003: biomarker and target of therapy.

By J. S. Ross, J. Fletcher, Gerald P. Linette, J. Stec, E. Clark, M. Ayers, W. Symmans, L. Pusztai, K. Bloom. The Oncologist, 2003

672 citations recorded by the source corpus.

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

The oncogene HER2: its signaling and transforming functions and its role in human cancer pathogenesis (2007, background): “These include increased sensitivity to certain cytotoxic chemotherapeutic agents, resistance to certain hormonal agents and increased propensity to metastasize to the brain (Ross et al., 2003; Gabos et al., 2006).”
EGF–ERBB signalling: towards the systems level (2006, background): “Likewise, overexpression of ERBB2 has been reported in breast, lung, pancreas, colon, endometrium and ovarian cance”
Meeting highlights: international expert consensus on the primary therapy of early breast cancer 2005. (2005, background): “Despite issues related to reproducibility of immunohistochemistry staining or FISH testing for HER2/neu, it was felt that HER2/neu status should be regarded as useful for patient care, with overexpression indicating a worsened prognosis [101].”
Derailed endocytosis: an emerging feature of cancer (2008, background): “gov/cancertopics/types/endometrial">endometrial and ovarian cancer and predicts poor prognosis for cancer patient”